Torren Management’s Roivant Sciences ROIV Stock Holding History

Torren Management’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-524	Closed	-$11.4K	–	1365
2025 Q4	$11.4K	Buy	+524	New	+$10.3K	0.01%	735

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Torren Management's ROIV Position: Q1 2026 in Review

Torren Management sold out of Roivant Sciences (ROIV) in Q1 2026, closing a stake of 524 shares — an estimated $11.4K sold.

Torren Management first reported a position in ROIV in Q4 2025 and held it in 1 quarter. The position peaked at $11.4K in Q4 2025. 441 funds tracked by Wall St. Rank hold ROIV as of Q1 2026.

Torren Management reported no remaining Roivant Sciences position as of Q1 2026 after selling out during the quarter.
Torren Management sold 524 Roivant Sciences shares in Q1 2026, an estimated $11.4K.
Torren Management first reported a position in Roivant Sciences in Q4 2025 and held it in 1 quarter.
Torren Management's Roivant Sciences position peaked at $11.4K in Q4 2025.
441 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.